Nova Eye Medical (ASX:EYE) — Material Events
ASX:EYE · 12 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Nova Eye Medical Surges to Record FY25 Revenue, Eyes Breakeven in H1 FY26Medium
Nova Eye Medical posts record FY25 revenue, targets breakeven EBITDA in H1 FY26
29 July 2025
·Quarterly Activities and Cashflow Report
·85
Nova Eye Medical’s Sales Surge 32%, Eyes China Market with New ApprovalMedium
Nova Eye Medical Q1 FY26 sales up 32%, iTrack™ Advance approved in China, EBITDA breakeven expected H2 FY26
31 Oct 2025
·Quarterly Activities and Cashflow Report
·85
Nova Eye Medical Posts Record FY25 Revenue, Eyes Breakeven in H1 FY26Medium
Nova Eye Medical reports record FY25 revenue, improved profitability, and positive FY26 guidance
29 July 2025
·Quarterly Activities and Appendix 4C Cash Flow Report
·85
Nova Eye Medical Posts Record FY25 Sales, Eyes Breakeven in H1FY26Medium
Nova Eye Medical posts record FY25 sales, targets breakeven EBITDA in H1FY26
27 Aug 2025
·Financial Results
·85
Nova Eye Medical Surges with Record US$6.1M Quarter, US Market Leads GrowthMedium
Nova Eye Medical posts record US$6.1M quarterly sales, 24% annual growth, driven by US market
12 Jan 2026
·Sales Update
·85
Nova Eye Medical Narrows EBITDA Loss with 23% Sales Growth and New US Product FeatureMedium
Nova Eye Medical posts 23% sales growth, narrows EBITDA loss, and launches new product feature
29 Apr 2026
·Quarterly Activities and Cashflow Report
·85
Nova Eye Medical Surges with Record US$6.1M Quarter and 24% Annual GrowthMedium
Nova Eye Medical posts record US$6.1M quarterly sales, 24% annual growth, expands manufacturing and clinical programs
29 Jan 2026
·Quarterly Activities and Cashflow Report
·85
Nova Eye Medical Lifts FY26 Sales Forecast After US April Sales RecordMedium
Nova Eye Medical upgrades FY26 sales guidance after record US sales in April 2026
5 May 2026
·Sales Guidance Upgrade
·85
Nova Eye Medical Secures Key Approval to Expand Glaucoma Device Sales in ChinaMedium
Nova Eye Medical's iTrack Advance Approved for Sale in China, Sales Growth Expected from FY26
30 Sept 2025
·Regulatory Approval Announcement
·80
Nova Eye Medical’s Q1 Revenue Climbs 20%, Eyes Breakeven by Mid-2026Medium
Nova Eye Medical Q1 FY26 revenue grows 20%, confirms FY26 guidance, targets breakeven EBITDA by June 2026
5 Nov 2025
·Investor Presentation
·75
Nova Eye Medical Hits FY25 Sales Targets with Strong US Growth and Margin GainsMedium
Nova Eye Medical meets FY25 sales guidance with strong US growth and improved margins; FY26 sales guidance set with breakeven EBITDA target
27 Aug 2025
·Investor Presentation
·75
No articles in this tier for the last 12 months.
Market Mentions
4
- appeared in market wrap coverage
These are market wrap articles where Nova Eye Medical (ASX:EYE) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 19 (4 May -> 8 May) 2026
9 May 2026
Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026
31 Jan 2026
Market Wrap - Week 3 (12 Jan -> 16 Jan) 2026
18 Jan 2026